Visit Us @
Synergy Centre TU Dublin, Tallaght, D24A386
Mail Us @
info@codlad.com
Call Us @
+353 851890752

Archive for May 11, 2023

FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease

May 11, 2023

FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease

Today, the U.S. Food and Drug Administration is announcing the supplemental approval of Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia…

FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease FDA
FDA Finalizes Move to Recommend Individual Risk Assessment to Determine Eligibility for Blood Donations

May 11, 2023

FDA Finalizes Move to Recommend Individual Risk Assessment to Determine Eligibility for Blood Donations

Today, the U.S. Food and Drug Administration finalized recommendations for assessing blood donor eligibility using a set of individual risk-based questions to reduce the risk…

FDA Finalizes Move to Recommend Individual Risk Assessment to Determine Eligibility for Blood Donations FDA

Latest Posts

FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome
FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome
March 25, 2026
FDA Schedules Public Meeting on the Commissioner’s National Priority Voucher Pilot Program
FDA Schedules Public Meeting on the Commissioner’s National Priority Voucher Pilot Program
March 20, 2026
FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide
FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide
March 19, 2026